BioCardia (BCDA) Advances CardiAMP Heart Failure Therapy in Japan After PDMA Advice

BioCardia Inc. (BCDA) announced on May 29, 2026, it received regulatory advice from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for its CardiAMP cell therapy candidate in treating ischemic heart failure. The agency’s feedback clarifies clinical data and manufacturing requirements, potentially streamlining the path toward a marketing application in the world’s second-largest pharmaceutical market. The consultation aligns the company’s development program with Japanese regulatory expectations, reducing late-stage uncertainty. CardiAMP uses a patient’s own bone marrow cells delivered via a minimally invasive catheter system. The therapy has shown promising results in U.S. clinical trials, and Japan’s aging population represents a significant commercial opportunity.